Anthem Biosciences Limited announced its unaudited financial results for the third quarter and nine months ended December 31, 2025. For the nine months ended December 31, 2025 (9MFY26), the consolidated revenue from operations stood at ₹15,134 Million (₹1513.4 crore), marking an 11.2% increase compared to the previous year. The CRDMO business contributed ₹12,599 Million (₹1259.9 crore) and the Specialty Ingredients business reported ₹2,535 Million (₹253.5 crore) in revenues. EBITDA for 9MFY26 was ₹6,712 Million (₹671.2 crore), with EBITDA margins at 41.5%. Profit After Tax (PAT) for the period was ₹4,020 Million (₹402.0 crore), resulting in PAT margins of 24.8%. The company maintained a net cash position of ₹12,312 Million (₹1231.2 crore) as of December 31, 2025. In the third quarter of FY26 (Q3FY26), consolidated revenue from operations was ₹4,232 Million (₹423.2 crore), a decrease of 15.0% year-on-year. EBITDA for the quarter was ₹1,907 Million (₹190.7 crore) with EBITDA margins at 41.8%. PAT for Q3FY26 stood at ₹928 Million (₹92.8 crore), with PAT margins at 20.3%. An exceptional item of ₹254 Million was recorded in the nine-month period related to the assessment and provision for the new Labour Codes notified by the Government of India. The company stated it will continue to monitor the finalization of these codes and ensure compliance.
